Oral olesoxime vs placebo
Adverse events related to treatment · non‐ambulatory children and adolescents with SMA types II and III
Oral olesoxime probably leads to lower adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.95 [0.91, 0.99]1 study · 165 participantsModerate